IDEXX Laboratories Stock Jumps on Testing Products Demand, Higher Prices

Core Insights - IDEXX Laboratories (IDXX) shares increased by 10% following better-than-expected results driven by demand for animal testing products and price increases [1][4] - The company reported fourth-quarter earnings per share (EPS) of $2.62 and revenue of$954.3 million, both surpassing Visible Alpha forecasts [1][4] Financial Performance - Revenue from the Companion Animal Group (CAG) grew by 6%, with CAG Diagnostics recurring revenue also up by 6% due to high-quality placements, customer retention, new business gains, and net price realization [2] - Water testing operations revenue rose by 8% attributed to net price improvement and solid gains in the U.S. and Europe [2] - For the full year, the company projects EPS between $11.74 and$12.24 and revenue between $4.055 billion and$4.170 billion, slightly below analyst expectations [3] Innovation and Future Outlook - CEO Jay Mazelsky highlighted that IDEXX is at the forefront of a new wave of major innovation, with a new Cancer Dx screening test for canine lymphoma set to launch in the U.S. and Canada in late March [2][4] - Despite the recent share price increase, IDEXX shares are still down approximately 12% over the past year [3]